Indonesian Political, Business & Finance News

Kimia Farma’s Losses Narrow by 94.49%: Here’s Why

| Source: CNBC Indonesia Translated from Indonesian | Business
Kimia Farma’s Losses Narrow by 94.49%: Here’s Why
Image: CNBC Indonesia

Jakarta, CNBC Indonesia — PT Kimia Farma (Persero) Tbk (KAEF) recorded sales of Rp7 trillion in the third quarter of 2026. Its operating profit stood at Rp227 billion, up 129.31% year on year from Rp99 billion in the same period a year earlier.

EBITDA also grew by 32.04% year on year to Rp503 billion, from Rp381 billion in the third quarter of 2025. Meanwhile, the company cut its net loss to Rp13 billion, an improvement of Rp221 billion compared with the net loss of Rp234 billion in the same period last year.

Kimia Farma president director Djagad Prakasa Dwialam said the company’s performance through the third quarter of 2026 showed positive progress in its ongoing transformation.

“The company’s performance through the third quarter of 2026 shows that the turnaround is progressing in a positive direction. Operating profit growth of 129.31% and EBITDA growth of 32.04% reflect a fundamental improvement in operational performance and the results of sustained efforts to improve business efficiency and effectiveness. We will maintain this momentum by strengthening our business fundamentals and ensuring that every step in the transformation delivers a tangible impact on the company’s sustainability,” Djagad said, as quoted on Monday (2 November 2026).

In addition to improving operating profit and EBITDA, the company significantly reduced its net loss. The net loss fell from Rp234 billion in the third quarter of 2025 to Rp13 billion in the same period of 2026, an improvement of around 94.49%.

“The reduction in net losses is an important development in Kimia Farma’s transformation. Our focus is not only on improving short-term financial results, but also on building a healthier business foundation, strengthening operational discipline and improving the company’s competitiveness so that it can grow sustainably,” Djagad added.

In the fourth quarter of 2026, the company will continue its governance transformation and focus on strengthening its business fundamentals. Measures will target stronger internal controls, risk management, decision-making discipline and accountability to support healthier, more sustainable corporate management.

On the business and financial front, the company will continue to strengthen working capital and liquidity management, control costs, improve asset productivity and optimise its product portfolio. These measures are intended to improve efficiency and the quality of operational performance, while bolstering competitiveness and laying the foundations for growth.

As part of its restructuring, the company is also continuing to address legacy challenges carefully and in a measured manner, in accordance with applicable regulations and good corporate governance principles. Its handling of these matters will take into account the interests of the company and its shareholders, as well as operational continuity.

More from 2 November 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/kimia-farmas-losses-narrow-by-94-49-heres-why-1793595046)
Originally published by CNBC Indonesia (https://www.cnbcindonesia.com/market/20261102085239-17-781389/rugi-kimia-farma--kaef--susut-9449-ini-penyebabnya), translated from Indonesian
Print